UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C 20549  FORM 10-Q  (Mark One)  [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 201531, 2014rch 31, 2014  [  ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ____ to ____  Commission File No. 333-144226  ARTVENTIVE MEDICAL GROUP, INC. (Exact name of registrant as specified in its charter) Nevada 26-0148468 (State or other jurisdiction (IRS Employer of incorporation or organization) Identification No.)  2766 Gateway Road, Carlsbad, California, 92009 (Address of principal executive offices) (760) 471-7700 (Registrants telephone number)  Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [x] No  [  ]  Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.  Large accelerated filer [  ] Accelerated filer [  ] Non-accelerated filer [  ] Smaller reporting company [ X ]  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes [  ]  No [x]  State the number of shares outstanding of each of the issuers classes of common equity, as of the latest practicable date:  As of November 3, 2015 there were 63,342,086 shares of the Companys common stock issued and outstanding.   PART I  FINANCIAL INFORMATION  Item 1.  Financial Statements.   ArtVentive Medical Group, Inc. Consolidated Financial Statements (Unaudited) For the Nine Month Periods ended September 30, 2015 and September 30, 2014   Consolidated Balance Sheets as of September 30, 2015 (unaudited) and December 31, 2014 Statement 1  Consolidated Statements of Operations and Comprehensive Loss (unaudited) for the three and nine-month periods ended September 30, 2015 and September 30, 2014  Statement 2  Consolidated Statements of Cash Flows (unaudited) for the nine-month periods ended September 30, 2015 and September 30, 2014 Statement 3   Notes to Consolidated Financial Statements (unaudited)    Statement 1 ArtVentive Medical Group, Inc. Consolidated Balance Sheets September 30, 2015 and December 31, 2014  ASSETSSeptember 30,2015
(unaudited)December 31,
2014CURRENTCash and cash equivalents$
53,005$ 104,030Accounts receivable57,29722,662Prepaid expenses1,0481,048Inventory304,41523,738TOTAL CURRENT ASSETS415,765151,478PROPERTY, PLANT AND EQUIPMENTOffice equipment23,80217,953Accumulated depreciation(8,804)(5,467)NET PROPERTY, PLANT AND EQUIPMENT14,99812,486OTHER ASSETSDeposits115,18225,007TOTAL OTHER ASSETS115,18225,007TOTAL ASSETS$
545,945$ 188,971LIABILITIES AND STOCKHOLDERS EQUITYCURRENT LIABILITESAccounts payable$
603,805$ 221,397Accrued expenses-1,043,300Payroll taxes payable61-TOTAL CURRENT LIABILITIES603,8661,264,697LONG-TERM LIABILITESNotes payable$
500,000$ 500,000TOTAL LONG-TERM LIABILITIES500,000500,000TOTAL LIABILITIES$
1,103,866$ 1,764,697  (See accompanying notes)    ArtVentive Medical Group, Inc.
Consolidated Balance Sheets
September 30, 2015 and December 31, 2014STOCKHOLDERS EQUITY (DEFICIT)Common stock, par value $.001, 100,000,000 sharesauthorized, 63,192,086 and 59,506,286 shares issued and   outstanding at September 30, 2015 and December 31, 2014, respectively$
63,192$ 59,506Additional paid in capital16,678,93012,879,982Retained deficit(17,300,043)(14,515,214)TOTAL STOCKHOLDERS EQUITY (DEFICIT)(557,921)(1,575,726)TOTAL LIABILITIES AND STOCKHOLDERS
EQUITY (DEFICIT)$
545,945$ 188,971  (See accompanying notes)


Statement 2 ArtVentive Medical Group, Inc. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) For the Three and Nine Months Ended September 30, 2015 and September 30, 2014  For the three months ended September 30, 2015For the three months ended
September 30, 2014For the nine months ended September 30, 2015For the nine months ended September 30, 2014REVENUES$  49,991$ 31,865$         208,176$            67,500COST OF GOODS SOLD49,99131,865208,17667,500GROSS PROFIT----OPERATING EXPENSESResearch and development599,6411,111,5261,225,7032,770,964Selling, general and administrative330,695466,8741,555,7932,118,973Depreciation expense1,1127713,3372,314OPERATING LOSS BEFORE OTHER ITEMS AND INCOME TAX(931,448)(1,579,171)(2,784,833)(4,892,251)OTHER INCOME/(EXPENSE)INTEREST INCOME2764694Income tax expense (benefit)----NET LOSS AVAILABLE TO COMMON STOCKHOLDERS(931,446)(1,579,095)(2,784,829)(4,891,557)COMPREHENSIVE LOSS FOR THE PERIOD$      (931,446)$
(1,579,095)$ (2,784,829)$    (4,891,557)BASIC AND DILUTED LOSS PER COMMON SHARE(0.01)(0.03)(0.05)(0.09)WEIGHTED AVERAGE SHARES OUTSTANDING61,735,63458,005,19960,176,83956,776,286


(See accompanying notes)


Statement 3 ArtVentive Medical Group, Inc. Consolidated Statements of Cash Flows (Unaudited) For the Nine Months Ended September 30, 2015 and September 30, 2014   For the nine months ended September 30,
2015For the nine months ended September 30,
2014CASH FLOW FROM OPERATING ACTIVITIESNet loss$ (2,784,829)$ (4,891,557)ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED BY OPERATING ACTIVITIESNon-cash expenses96,834-Depreciation expense3,3372,314CHANGES IN OPERATING ASSETS AND LIABILITIESAccounts receivable(34,635)(9,450)Prepaid expenses-8,050Inventory(280,677)(212,851)Deposits(90,175)(29,449)Accounts payable382,40813,893Accrued expenses(37,500)-Payroll taxes payable61-NET CASH USED BY OPERATING ACTIVITIES(2,745,176)(5,119,050)CASH FLOWS FROM INVESTING ACTIVITIESPurchase of equipment(5,849)-NET CASH USED BY INVESTING ACTIVITIES(5,849)-CASH FLOWS FROM FINANCING ACTIVITIESIssuance of common stock for cash2,700,0003,200,000Issuance of notes payable-500,000Convertible note payable (see Note 4)--NET CASH PROVIDED BY FINANCING ACTIVITIES2,700,0003,700,000NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS(51,025)(1,419,050)CASH, BEGINNING OF PERIOD104,0301,626,521CASH, END OF PERIOD$ 53,005$        207,471CASH FLOWS FROM FINANCING ACTIVITIESInterest paid$-$-Income taxes paid$                  800$                800NON-CASH INVESTING AND FINANCING ACTIVITIESSTOCK ISSUED UPON CONVERSION OF NOTE PAYABLE$                      -$ -TRANSFER OF STOCK FOR ACCRUED ISSUANCE COST$ (1,070,800)$ -ACCRUAL OF STOCK ISSUANCE COST$            65,000$ 320,000


(See accompanying notes)


ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015  1. BASIS OF FINANCIAL STATEMENT PRESENTATION  The accompanying unaudited condensed consolidated financial statements have been prepared by ArtVentive Medical Group, Inc. the Company pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations.  The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements.  Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed consolidated financial statements be read in conjunction with the Company's audited financial statements and notes thereto included in its Form 10-K filed on March 31, 2015.  Operating results for the nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the fiscal year ended December 31, 2015.  2. ORGANIZATION  ArtVentive Medical Group, Inc. (the Company), is a Nevada Corporation traded on the OTCQB (symbol AVTD).  On January 9, 2010, the Company completed the acquisition of all of the assets of ArtVentive Medical Inc., a California company.  The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Companys fiscal year end is December 31.  The Company is a medical device corporation, focused on developing, manufacturing and marketing a family of Endoluminal Occlusion Devices (EOSTM).  Through its innovative, proprietary technology the Company has developed unique minimally invasive occlusion devices and procedures, bringing the current interventional, image guided techniques to a new level of sophistication, potentially resolving significant and unaddressed health issues. The EOS device being developed by the Company targets a substantive market demand in several major clinical areas, including women's health, peripheral and neurological vascular disorders, and interventional cardiology procedures.  To date, the Companys activities have been committed to the development of the EOSTM, intellectual property, animal studies, human studies, patent filings, manufacturing, sales, marketing and implementing its regulatory strategy for clinical      ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015  indications for  European regulatory and FDA submissions and approval, corporate operations and the raising of equity capital.  The Company conducted the required human clinical studies during 2011 achieving 100% clinical and procedural success, validating the safety and efficiency of the ArtVentive EOSTM device.  On August 3, 2011, the Company incorporated ArtVentive Womens Health Group, Inc., a wholly owned subsidiary of the Company.  The Company received its CE Mark certification for the ArtVentive EOS Peripheral device on May 30, 2013, and implemented the planned EOS peripheral device transfer from Research and Development to commercialization, marketing, and distribution throughout Europe, simultaneous to making its FDA application.   The Company received FDA approval for the ArtVentive EOS Peripheral device on December 3, 2014.  The Company filed additional patent applications expanding its patent reach of the ArtVentive EOS device to 24 patents or patent applications.    3. SIGNIFICANT ACCOUNTING POLICIES  PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the transactions of the Company and its subsidiary.  All inter-company accounts and transactions have been eliminated in consolidation.   USE OF ESTIMATES The preparation of the Companys financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.  Actual results could differ from those estimates.  The Companys periodic filings with the Securities and Exchange Commission include, where applicable, disclosures of estimates, assumptions, uncertainties and markets that could affect the financial statements and future operations of the Company.     ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015   COMMON STOCK ISSUED FOR OTHER THAN CASH Services purchased and other transactions settled in the Companys common stock and stock options are recorded at the estimated fair value of the stock issued and options granted if that value is more readily determinable than the fair value of the consideration received.  EARNINGS PER SHARE OF COMMON STOCK In accordance with accounting guidance now codified as FASB ASC Topic 260, Earnings per Share, basic earnings (loss) per share is computed by dividing net income (loss) by weighted average number of shares of common stock outstanding during each period.  Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period.  The Company had the following potential common stock equivalents at September 30, 2015:  Common stock warrants 3,700,000 Common stock options 330,000 Convertible notes payable 523,097 Total common stock equivalents 4,553,097  Since the Company reflected a net loss as of September 30, 2015 and 2014, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive.  A separate computation of diluted earnings (loss) per share is not presented.  The following table sets forth the computation of earnings per share:   Sept. 30, 2015           Sept. 30, 2014  Net income (loss)                                                     $    (2,784,289)           $      (4,891,557)      Weighted average common shares outstanding       60,176,839                   56,776,286  Net (loss) per share                                                  $       (0.05)               $            (0.09)    ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015    PROPERTY AND EQUIPMENT The Company records property and equipment at cost and uses straight-line depreciation methods.  Estimated Useful LivesSeptember 30, 2015December 31, 2014Computer equipment

Office furniture5 years

7 years$     19,056

4,746$    13,207

4,746Less accumulated depreciation(8,804)(5,467)Net property and equipment$     14,998$     12,486   INVENTORY The Companys inventory is valued at the lower of cost or market using the first-in, first-out (FIFO) method.  As of September 30, 2015 and December 31, 2014, all inventory consisted of finished goods.  As the Company begins its transition from the Research and Development phase to production, management has estimated the cost of units sold to be equal to the revenue generated on those units.  Other direct cost that may be associated with the production of these units has been reflected in Research and Development expenses.   FOREIGN CURRENCY TRANSLATIONS The Companys functional and reporting currency is the US dollar.  All transactions initiated in other currencies are translated into US dollars using the exchange rate prevailing on the date of transaction.  Monetary assets and liabilities denominated in foreign currencies are translated into the US dollar at the rate of exchange in effect at the balance sheet date.  Unrealized exchange     gains and losses arising from such transactions are deferred until realization and are included as a separate component of stockholders equity (deficit) as a component of other comprehensive income or loss. Upon realization, the amount deferred is recognized in income in the period when it is realized.    ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015     CASH AND CASH EQUIVALENTS Cash and cash equivalents consist principally of funds on hand, deposit with banks and liquid investment funds having maturity of three months or less at the time of the purchase.  The Company has no cash equivalents.  The Company had funds on deposit of $53,005 at September 30, 2015.   REVENUE RECOGNITION Revenue for the sale of goods in the course of the ordinary activities is measured at the fair value of the consideration received or receivable, net of returns.  Revenue for sale of goods is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of the goods can be estimated reliably, there is no continuing involvement with the goods, and the amount of the revenue can be measured reliably.    CONCENTRATION OF RISK Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash.  The Company maintains cash balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits of $250,000. As of September 30, 2015 and December 31, 2014, the Company had no deposits in excess of federally insured limits in its US bank.  The Company has not experienced any losses with regard to its bank accounts and believes it is not exposed to any risk of loss on its cash in bank accounts.                   ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015   4. NOTE PAYABLE  On April 1, 2014, the Company borrowed $250,000 from an unrelated party and issued a note payable on or before December 31, 2014, with interest at 3% per annum.  On December 31, 2014, the Company and the lender executed an extension of the note, which is now due on or before December 31, 2017.  The interest remains at 3%.  The lender may convert all or part of the debt, including interest, into common stock of the Company at any time at the rate of $1 per share.  On April 1, 2014, the Company borrowed $250,000 from an unrelated party and issued a note payable on or before December 31, 2014, with interest at 3% per annum.  On December 31, 2014, the Company and the lender executed an extension of the note, which is now due on or before December 31, 2017.  The interest remains at 3%.  The lender may convert all or part of the debt, including interest, into common stock of the Company at any time at the rate of $1 per share.   September  30,   2015December 31, 2014Note payable to private party, with interest at 3.0%, with the balance, interest and principal, due December 31, 2017$   250,000$       250,000Note payable to private party, with interest at 3.0%, with the balance, interest and principal, due December 31, 2017250,000250,000Total500,000500,000Less current maturities of long-term debt--Noncurrent maturities of long-term debt$   500,000$        500,000  Maturities on long-term debt are as follows:  2015$              -2016-2017$  500,000$  500,000            ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015  5. SHARE CAPITAL  Effective January 7, 2014, 400,000 shares were issued in a private placement for the receipt of $400,000. Effective February 11, 2014, 400,000 shares were issued in a private placement for the receipt of $400,000. Effective March 6, 2014, 300,000 shares were issued in a private placement for the receipt of $300,000. Effective May 23, 2014, 100,000 shares were issued in a private placement for the receipt of $100,000. Effective June 24, 2014, 1,000,000 shares were issued in a private placement for the receipt of $1,000,000. Effective July 23, 2014, 500,000 shares were issued in a private placement for the receipt of $500,000. Effective August 29, 2014, 250,000 shares were issued in a private placement for the receipt of $250,000. Effective September 29, 2014, 150,000 shares were issued in a private placement for the receipt of $150,000. Effective September 30, 2014, 100,000 shares were issued in a private placement for the receipt of $100,000. Effective October 15, 2014, 100,000 shares were issued in a private placement for the receipt of $100,000 Effective November 7, 2014, 80,000 shares were issued in a private placement for the receipt of $80,000. Effective November 28, 2014, 70,000 shares were issued in a private placement for the receipt of $70,000. Effective December 4, 2014, 250,000 shares were issued in a private placement for the receipt of $250,000. Effective December 15, 2014, 250,000 shares were issued in a private placement for the receipt of $250,000 Effective December 29, 2014, 250,000 shares were issued in a private placement for the receipt of $250,000     Effective January 23, 2015, 250,000 shares were issued in a private placement for the receipt of $250,000.    ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015  Effective February 27, 2015, 150,000 shares were issued in a private placement for the receipt of $150,000 Effective March 15, 2015, 100,000 shares were issued in a private placement for the receipt of $100,000 Effective March 31, 2015, 150,000 shares were issued in a private placement for the receipt of $150,000 Effective April 23, 2015, 150,000 shares were issued in a private placement for the receipt of $150,000. Effective May 4, 2015, 100,000 shares were issued in a private placement for the receipt of $100,000. Effective May 5, 2015, 960,800 shares were issued for $1,070,800 of prior years' accrued issuance costs. Effective May 29, 2015, 500,000 shares were issued in a private placement for the receipt of $500,000. Effective June 1, 2015, 500,000 shares were issued in a private placement for the receipt of $500,000. Effective July 17, 2015, 200,000 shares were issued in a private placement for the receipt of $200,000. Effective August 8, 2015, 50,000 shares were issued in a private placement for the receipt of $50,000 on April 16, 2015. Effective August 27, 2015, 300,000 shares were issued in a private placement for the receipt of $300,000. Effective September 28, 2015, 250,000 shares were issued in a private placement for the receipt of $250,000.   6. GOING CONCERN AND LIQUIDITY CONSIDERATIONS The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.  As of September 30, 2015, the Company has a negative working capital balance of $188,101 and an accumulated deficit of $17,300,043.  The Company intends to fund operations through equity financing arrangements, which should be sufficient to fund its capital expenditures, working capital and other cash requirements for the next twelve months.     The ability of the Company to implement its business plan is dependent upon, among other things, obtaining additional financing to continue operations, research and development and production of its product.  ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015  The Company has a present offering to shareholders for 15,000,000 shares, of which 11,118,000 has been subscribed to date.  The Company continues to offer the remaining 3,832,000 shares to those shareholders.  With other potential future financing, management believes these initiatives alleviate the substantial doubt regarding the Companys ability to continue as a going concern.    7. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS  Accounting Standards Updates (ASU) ASU No. 2015-16 which contain technical corrections to existing guidance or affect guidance to specialized industries or entities were recently issued. These updates have no current applicability to the Company or their effect on the financial statements would not have been significant.   8. PROVISION FOR INCOME TAXES  The Company recognizes the tax effects of transactions in the year in which such transactions enter into the determination of net income, regardless of when reported for tax purposes.  Deferred taxes are provided in the financial statements under ASC Topic 740 to give effect to the resulting temporary differences which may arise from differences in the bases of fixed assets, depreciation methods, allowances, and start-up costs based on the income taxes expected to be payable in future years. Minimal exploration stage deferred tax assets arising as a result of net operating loss carry forwards have been offset completely by a valuation allowance due to the uncertainty of their utilization in future periods.  The Company adopted the provisions of ASC Topic 740 Accounting for Uncertainty in Income Taxes, on January 23, 2007 (inception date).  As a result of the implementation of ASC 740, the Company recognized no increase in the liability for unrecognized tax benefits. Operating loss carry-forwards generated during the period of January 23, 2007 (date of inception), through September 30, 2015, of approximately $17.1 million, will begin to expire in 2027.  Accordingly, deferred tax assets of approximately $7.1 million related to net operating loss carry-forwards, and approximately $215,000 related to stock-based     compensation were offset by the valuation allowance in the same amount.  For the nine months ended September 30, 2015 and 2014, the allowance increased by approximately $1,200,000 and $1,419,000, respectively.  ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015  The Company adopted the provisions of FASB Interpretation No. 48 Accounting for Uncertainty in Income Taxes, on January 23, 2007.  As a result of the implementation of Interpretation 48, the Company recognized no increase in the liability for unrecognized tax benefits. The Company has no tax positions at September 30, 2015, or December 31, 2014, for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Companys tax returns for the years ended December 31, 2014, 2013, 2012 and 2011 are open for examination under Federal Statute of Limitations and for the years ended December 31, 2014, 2013 and 2012 under the State of California Statute of Limitations. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company had no accruals for interest and penalties since inception.  Components of income tax benefits are as follows:  Years Ended December 31,20142013$         -$       ---------  9. WARRANTS AND OPTIONS  Warrants:     During the fiscal year ended December 31, 2014, the Company granted 4,200,000 warrants to purchase shares of Common Stock which all have a 1 year exercise term, of which 3,700,000 remain outstanding at September 30, 2015.  During the quarter ended September 30, 2015, 750,000 warrants were issued.  The Company valued all warrants utilizing a Black-Scholes option pricing model and the fair value was recorded in additional paid-in capital. ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015 The following is a summary of the Companys warrant activity: WarrantsWeighted Average Exercise PriceExercisable  December 31, 20134,358,000$           1.50Granted-20144,200,000$           1.50Exercised-2014--Forfeited-2014(4,358,000)$           1.50Outstanding  December 31, 20144,200,000$           1.50Exercisable  December 31, 20144,200,000$           1.50WarrantsWeighted Average Exercise PriceGranted-2015 (at September 30, 2015)2,700,000$           1.50Exercised-2015 (at September 30,2015)--Forfeited-2015 (at September 30, 2015)(3,200,000)$           1.50Outstanding  September 30, 20153,700,000$           1.50Exercisable  September 30, 20153,700,000$           1.50             Warrants outstanding and exercisable at September 30, 2015 are as follows:  Warrants OutstandingWarrants ExercisableRange of
Exercise PriceNumber
OutstandingWeighted Average
Remaining Contractual
Life (in Years)Weighted Average
Exercise PriceNumber
ExercisableWeighted Average
Exercise Price$1.50100,0000.04 years$1.50100,000$1.50$1.5080,0000.10 years$1.5080,000$1.50$1.5070,0000.16 years$1.5070,000$1.50$1.50250,0000.17 years$1.50250,000$1.50$1.50250,0000.21 years$1.50250,000$1.50$1.50250,0000.25 years$1.50250,000$1.50$1.50250,0000.31 years$1.50250,000$1.50$1.50150,0000.41 years$1.50150,000$1.50$1.50100,0000.45 years$1.50100,000$1.50$1.50150,0000.50 years$1.50150,000$1.50$1.5050,0000.54 years$1.5050,000$1.50$1.50150,0000.56 years$1.50150,000$1.50      $1.50100,0000.59 years$1.50100,000$1.50$1.50500,0000.65 years$1.50500,000$1.50$1.50500,0000.67 years$1.50500,000$1.50$1.50200,0000.79 years$1.50200,000$1.50$1.50300,0000.91 years$1.50300,000$1.50$1.50250,0000.99 years$1.50250,000$1.50 ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015  Warrant activity is as follows: Effective October 15 2014, 100,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective November 7, 2014, 80,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective November 28, 2014, 70,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective December 4, 2014, 250,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective December 15, 2014, 250,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective January 3, 2015, 250,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective January 23, 2015, 250,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective January 30, 2015, 150,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective March 15, 2015, 100,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective March 31, 2015, 150,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year     Effective April 16, 2015, 50,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year  ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015  Effective April 23, 2015, 150,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective May 4, 2015, 100,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective May 28, 2015, 500,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective June 1, 2015, 500,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective July 17, 2015, 200,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective August 27, 2015, 300,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year Effective September 28, 2015, 250,000 warrants were issued.  The warrants allow the purchase of common shares at an exercise price of $1.50.  There is no vesting period, and the warrants expire in 1 year                ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015 Stock Options:  During the period that the options were issued, the Company had no public trading activity for the Companys common stock.  However, the Company sold in private transactions shares at $1.00 per share.  In order to value the Companys options, the Company chose to use the minimum value method, even though the Company is a public company since there was no measurable trading activity.  The fair value of the options was recorded in additional paid-in capital.  Options outstanding and exercisable at September 30, 2015 are as follows:  OptionsWeighted
Average Exercise PriceOutstanding  December 31, 2013305,000$
0.836Exercisable  December 31, 2013105,000$
0.524Granted-2014-$
-Exercised-2014--Forfeited-2014--Outstanding  December 31, 2014305,000$
0.836Exercisable  December 31, 2014155,000$
0.678OptionsWeighted Average Exercise PriceGranted-2015 (at September 30, 2015)275,000$                      1.00Exercised-2015 (at September 30, 2015)(50,000)$                      0.001Forfeited-2015 (at September 30, 2015)(200,000)$
1.00Outstanding  September 30, 2015330,000$
1.00Exercisable  September 30, 2015230,000$
1.00               Options outstanding and exercisable at September 30, 2015 are as follows:  Options OutstandingOptions ExercisableRange of
Exercise PriceNumber
OutstandingRemaining Contractual
Life (in Years)Weighted Average
Exercise PriceNumber
ExercisableWeighted Average
Exercise Price$1.0035,0002.34 years$1.0035,000$1.00$1.0050,0000.24 years$1.0050,000$1.00$1.0010,0002.42 years$1.0010,000$1.00$1.0010,0003.24 years$1.0010,000$1.00      $1.0010,0009.32 years$1.0010,000$1.00$1.00100,0009.58 years$1.00100,000$1.00$1.0015,0009.91 years$1.0015,000$1.00$1.00100,0009.98 years$1.00-$1.00            ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015  Stock option activity is as follows: Effective November 2, 2010 the Board of Directors of the Company granted 50,000 non-statutory stock options to a former consultant at an exercise price of $.001 per share with the vesting date of November 2, 2013 and an expiration date of November 2, 2016.  These options were exercised on August 7, 2015. Effective February 1, 2013 the Board of Directors of the Company granted 20,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of February 1, 2013 and an expiration date of February 1, 2018.  Effective February 1, 2013 the Board of Directors of the Company granted 5,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of February 1 2013 and an expiration date of February 1, 2018.  Effective February 1, 2013 the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of February 1 2013 and an expiration date of February 1, 2018.  Effective March 1, 2013 the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of March 1, 2013 and an expiration date of March 1, 2018.  Effective December 1, 2013 the Board of Directors of the Company granted 200,000 non-statutory incentive stock options to a current employee at an exercise price of $1.00 per share with 50,000 of the shares vested on January 1, 2015 and the additional 75% of shares exercisable on each of the next succeeding three anniversaries of January 1.    The 50,000 vested stock options remain outstanding, while the 150,000 non-vested  options were forfeited through a voluntary resignation on September 4, 2015.  Effective December 27, 2013 the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of December 27, 2013 and an expiration date of December 27, 2018.  Effective January 1, 2015 the Board of Directors of the Company granted 50,000 non-statutory incentive stock options to a current employee at an exercise price of $1.00 per share with 25% of the shares vested on January 1, 2016 and an additional 25% of shares exercisable on each of the next succeeding three anniversaries of January 1.  The 50,000 non-vested  options were forfeited through a voluntary resignation on September 4, 2015.        ArtVentive Medical Group, Inc. Notes to Consolidated Financial Statements (Unaudited) September 30, 2015   Effective January 23, 2015 the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of January 23, 2015 and an expiration date of January 23, 2025.  Effective April 30, 2015 the Board of Directors of the Company granted 100,000 non-qualified stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of April 30, 2015 and an expiration date of April 30, 2025   Effective August 28, 2015, the Board of Directors of the Company granted 15,000 non-qualified stock options to a current board advisor at an exercise price of $1.00 per share with the vesting date of August 31, 2105, and an expiration date of August 31, 2025  Effective September 22, 2015, the Board of Directors of the Company granted 100,000 non-qualified stock options to a current consultant at an exercise price of $1.00 per share with 25% of the shares vesting on September 22, 2016 and an additional 25% of shares exercisable on each of the next succeeding three anniversaries of September 22, with the full portion exercisable on and after September 22, 2019 and an expiration date of September 22, 2025.  10.  SUBSEQUENT EVENTS  The Company evaluated all events or transactions that occurred after September 30,   2015, up through the date these consolidated financial statements were issued.  Effective October 28, 2015, the Company issued 150,000 shares in a private placement   for a receipt of $150,000.                Item 2.  Managements Discussion and Analysis of Financial Condition and Results of Operations  ArtVentive Medical Group, Inc. (the Company), is a Nevada Corporation traded on the OTCQB (symbol AVTD).  On January 9, 2010, the Company completed the acquisition of all of the assets of ArtVentive Medical Inc., a California company.  The Company remains focused on developing, manufacturing and marketing a family of Endoluminal Occlusion devices (EOS).  The Company, through its proprietary technology has developed minimally invasive occlusion devices and procedures, allowing for the current interventional, image guided techniques to resolve potentially significant and unaddressed health issues.  The ArtVentive EOS Peripheral device was developed by the Company to target the arterial and venous embolization peripheral vasculature markets.  The Company is currently expanding its EOS development to encompass several additional major clinical areas, including, but not limited to neuro vascular disorders, interventional oncology, women's health and interventional cardiology procedures.  The Company believes that it is well under way with the continued development and expansion of the ArtVentive EOS peripheral device by developing a second generation of the device (Generation II).  The new advanced device will have enhanced profile reductions from the current 6fr to a 5fr and 4fr (for some applicable sizes) catheter, while expanding the opportunity to advance into new areas in treating a larger range of vessel sizes, expanding clinical applications and market opportunities.   The Generation II EOS technology will add additional sizes to its current EOS portfolio of 5mm, 8mm and 11mm to include the ability of treating vessels in the range of 2mm to 20mm, while achieving a lower profile for the device.  The Company has contracted, and expects to continue contracting with specific American and European corporations and consulting groups to assist in the implementation of an ongoing strategic plan for the successful international market development, commercialization and manufacturing of the Companys products.  The Company entered into an agreement with Chicago, Illinois based Medical Murray Inc., a leader in the field of medical device development and manufacturing.  Medical Murray Inc. is recognized as being ISO certified and FDA registered.  The Company entered into an agreement with the Northwest Clinical Research Group, Inc. (NCRG), located in Seattle, Washington.  NCRG has played an intricate role in building the complex infrastructure and support necessary for outlining the regulatory and clinical strategy, in addition to providing a platform of quality controls parallel and synergistic to what Medical Murray is providing.  In May 2015, AlvaMed Corporation acquired NCRG with headquarters located in Dover, Massachusetts.  AlvaMed is highly recognized for their expertise in medical device quality assurance, regulatory, clinical affairs, and M&A due diligence.  Their responsibility extends to encompass communication with the FDA and the European Notified Body (FDA counterpart).      The Company implemented its Quality Management System (QMS), based on the requirements of, and is intended to comply with, the following regulations and international standards: · US FDA Quality System Regulation, 21 CFR 820  · EU Medical Device Directive (MDD), EEC 93/42  · Canada Medical Devices Regulations (CMDR), SOR/98-282  · ISO 13485:2003 Medical Devices  Quality Management Systems - Requirements Regulatory Purposes  A Document Control System and Design History File for the EOS project are in a continuous process of implementation.  The secured system utilizes Egnyte software and is hosted on the NCRGs server.  The Company completed a comprehensive ISO Certification audit performed by BSI Product Services.  BSI is an international ISO 9000/ISO Registrar and CE Mark Notified Body required for the European Regulatory approval and subsequent CE Mark certification.  The audit confirmed that the Companys Document and Quality control systems were to ISO standards, and in compliance with international requirements for the maintaining quality of the products without non-conformities.  The Company received its CE Mark certification for the ArtVentive EOS Peripheral device on May 30, 2013, and implemented the planned EOS peripheral device transfer from Research and Development to commercialization, marketing, and distribution throughout Europe, simultaneous to making its FDA application.   The Company received FDA approval for the ArtVentive EOS Peripheral device on December 3, 2014 and again on September 29, 2015, when expanding the EOS offering of sizes to include the 11mm device.  The Company filed additional patent applications expanding its patent reach of the ArtVentive EOS device to 24 patents or patent applications.  The Company filed an International patent application expanding the patent reach of its ArtVentive EOS device for contraception as it prepares the foundation for the launch of the Womens Health division during 2016.  In addition, the Company received confirmation of its registration of the ArtVentive trademark for China.  The Company launched a Post Market Surveillance Study throughout Europe.. This clinical program is progressing, and designed to collect confirmatory data in support of the safety and performance of the ArtVentive Medical Group Endoluminal Occlusion System  EOS.  Additional post market studies will commence in the US now that FDA approval has been received.  The OCCLUDE I registry is dedicated to venous indications with up to 40 subjects to be enrolled with a maximum of 20 subjects per center. The OCCLUDE II registry focuses on arterial     indications with up to 40 subjects to be enrolled in each study with a maximum of 20 subjects per center.  The Company currently has agreements encompassing twenty-four European countries.  Management is in the process of executing similar distribution agreements for several other European countries.  On August 3, 2011, the Company incorporated the ArtVentive Womens Health Group, Inc., a wholly owned subsidiary of the Company.  Mr. van der Laak joined the Company in September 2014 as the Director of Sales for Europe. In 2015 the Compnay began to lay the foundation for expansion into the USA markets, and in June 2015 Mr. Tyson Brill was added as a territoral representative in the Chicago region. The Company has developed a customized, comprehensive technology platform that will support management, distribution, sales and marketing globally by implementing a far-reaching Customer Relation Management (CRM) System. The integrated Sales and Management Platform is comprised of three modules, each designed to be complimentary to the others, cloud-based and providing a high level of controlled information and intelligence to advance the Companys information platform, marketing, sales and services to the interventional markets.  Management also reports that it had contracted with SalesForce.com, a global leader in CRM solutions and Financial Force, a leading provider of accounting, supply chain, human capital management and other solutions. This cloud-based platform eliminates the need for the Company to make a significant investment in hardware, software and personnel to manage customer information.   The Companys management can access the customized applications via their laptop, iPad or iPhone. Management showcased the ArtVentive EOS system during its launch into the US markets when it attended the Society of Interventional Radiology (SIR) Annual Scientific Meeting in Atlanta, Georgia in early March, and through its distribution partners when it attended the 18th European Vascular Conference in Maastricht, the Netherlands during mid-March 2015.The Company continued its directive to expand its reach into global markets by participating in the Charing Cross International Symposium (CX) in London during April 2015, and the CIRSE conference in Lisbon, Portugal during September 2015.  Results of Operations  During the second quarter of 2015, management amended research and development expenditures in line with its continued development and regulatory submission of the ArtVentive EOS Peripheral device.  The Company has continued its focus on the European market expansion and USA launch of the EOS device, which requires the raising of additional financing for its continued business development, including reimbursement, sales, marketing, branding, distribution, clinical studies, commercialization and ongoing Regulatory submissions.      The following summary are the results of operations, for the three and nine-month periods ended September 30, 2015 and 2014, and should be read in conjunction with the audited consolidated financial statements, for the year ended December 31, 2014, as included in our Form 10-K.  Financial results for the three and nine-month periods ended September 30, 2015 and 2014, are summarized as follows:  For the three months
ended September 30thFor the nine months
ended September 30th2015201420152014Operating revenues$49,991$31,865$208,176$67,500Operating expenses931,4481,611,0362,784,8334,959,751Operating income (loss)(931,448)(1,579,171)(2,784,833)(4,892,251)Other income (expense)2764694Provision for income tax----Net Income (Loss)$(931,446)$(1,579,095)$(2,784,829)$(4,891,557)  Revenue  Revenue commenced during first quarter 2014 and is derived solely from the sales of EOS devices.  The Companys revenues of $49,991 were for the three months ending September 30, 2015, compared to revenues of $31,865 for the three months ending September 30, 2014.        Expenses  The Companys total operating expenses for the three and nine-month periods ended September 30, 2015 and 2014 are outlined in the table below:   For the three months
ended September 30,For the nine months
ended September 30,2015201420152014Research and development599,6411,111,5261,225,7032,770,964Salaries and wages----Depreciation1,1127713,3362,314Professional fees----General and administrative330,695466,8741,555,7932,118,973Total$931,448$1,579,171$2,784,833$4,892,251      Research and development costs decreased by $511,885 for the three months ending September 30, 2015 from the comparative period of 2014.  Management expects research and development costs to be maintained in the future due to the enhancement of current products and the development of new devices.  The Company expects wages and salaries to increase substantially in the next three and twelve months as it adds additional employees and sales consultants for its sales, marketing and manufactured products.  Management projects manufacturing costs to decrease over the next twelve months as it perfects its production capabilities. The Company anticipates continued professional fees, mainly from regulatory, legal and accounting, due to ongoing SEC reporting requirements.  General and administrative fees are for ongoing office expenses and other operating costs not directly related to the manufacturing costs.   Such fees decreased by $563,179 for the nine months ended September 30, 2015 from the comparative period 2014 which is in line with its shift in focus from initial set up to sales and distribution.  Liquidity and Capital Resources  General  As of September 30, 2015, the Company had $53,005 in cash and cash equivalents.  The Company does not expect its current cash and operating income to be sufficient to meet its financial needs for continuing operations over the next twelve months.  To meet its need for cash management will need to raise additional funds.  Management anticipates that it will require an additional $10,000,000 over the next twelve months to further develop its devices and increased manufacturing projections.        Liquidity and Financial Condition  Working CapitalAtAtSeptember 30,September 30,Increase/20152014(Decrease)Current Assets$415,765$457,723$(41,958)Current Liabilities$603,866$1,192,202$(588,336)Working Capital/( Deficit)$(188,101)$(734,479)$(546,378)  Cash FlowsNine Months Ended September,20152014Net Cash Used in Operating Activities$(2,745,176)$(5,119,050)Net Cash Used in Investing Activities$(5,849)$-Net Cash Provided by (Used in) Financing Activities$2,700,000$3,700,000      Net Increase (decrease) in Cash During the Period$(51,025)$(1,419,050)  The Company has no known demands or commitments and is not aware of any events or uncertainties as of September 30, 2015, that will result in or that are reasonably likely to materially increase or decrease our current liquidity.  Limited Operating History  There is no historical financial information about the Company on which to base an evaluation of our performance.  The Company has generated minimal revenues from operations.  Management cannot guarantee that it will be successful in its business operations.  The business is subject to risks inherent in the medical device business enterprise in a highly competitive industry, including limited capital resources, and possible cost overruns due to the price and cost increases in supplies and services.  The Company believes it does not have enough cash on hand or will be able to generate enough income from operations to pay operating costs for the next twelve months.  In order to carry out our business plan, including manufacturing our medical devices, we will be required to seek equity or debt financing. If management is to raise sufficient funds to increase its manufacturing and deliver products, as well as enhance and develop new innovative devices, the Company will have to curtail its operations until such funds are received.  There is no guarantee that the Company will be successful in raising such funds.  Item 3. Quantitative and Qualitative Disclosure about Market Risk  Not required by smaller reporting companies.     Item 4.  Controls and Procedures  As of the end of the period covered by this report, AVTD carried out an evaluation of the effectiveness of the Companys disclosure controls and procedures (as defined by Rule 13-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) under the supervision and with the participation of ArtVentive Medical Groups President and Principal Financial Officer.  Based on and as of the date of such evaluation, the aforementioned officers have concluded that ArtVentive Groups disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act.  There were no significant changes in AVTDs internal controls or in other factors that could significantly affect these controls during the third quarter ended September 30, 2015.  There were no significant deficiencies or material weaknesses, and therefore there were no corrective actions taken.  It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the     system are met.  In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events.  Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.      PART II  INFORMATION  Item 1.  Legal Proceedings  None  Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds  On April 16, 2015, we issued 50,000 shares of common stock to an unaffiliated shareholder for a purchase price of $50,000, plus a warrant to purchase 50,000 shares of common stock for $1.50 per share  On April 23, 2015, we issued 150,000 shares of common stock to an unaffiliated shareholder for a purchase price of $150,000, plus a warrant to purchase 150,000 shares of common stock for $1.50 per share.  On May 4, 2015, we issued 100,000 shares of common stock to an unaffiliated shareholder for a purchase price of $100,000, plus a warrant to purchase 100,000 shares of common stock for $1.00 per share.  On May 29, 2015, we issued 500,000 shares of common stock to an unaffiliated shareholder for a purchase price of $500,000, plus a warrant to purchase 500,000 shares of common stock for $1.50 per share.  On June 7, 2015, we issued 500,000 shares of common stock to an unaffiliated shareholder for a purchase price of $500,000, plus a warrant to purchase 500,000 shares of common stock for $1.50 per share.  On May 5, 2015, we issued 960,800 shares of common stock to a non-affiliate consultant for services rendered at an issue price of $.001 per share.  On July 17, 2015, we issued 200,000 shares were issued in a private placement for the receipt of $200,000.  On July 17, 2015, we issued 200,000 shares of common stock to an unaffiliated shareholder for a purchase price of $200,000, plus a warrant to purchase 200,000 shares of common stock for $1.50 per share.  On August 6, 2015, we issued 50,000 shares of common stock to an unaffiliated shareholder for a purchase price of $50,000, plus a warrant to purchase 50,000 shares of common stock for $1.50 per share, for funds received on April 6, 2015.  On August 11, 2015, we issued 25,000 shares to a non-affiliate consultant for services rendered at an issue price of $.001 per share.       On August 27, 2015, we issued 300,000 shares of common stock to an unaffiliated shareholder for a purchase price of $300,000, plus a warrant to purchase 300,000 shares of common stock for $1.50 per share.  On September 28, 2015, we issued 250,000 shares of common stock to an unaffiliated shareholder for a purchase price of $250,000, plus a warrant to purchase 250,000 shares of common stock for $1.50 per share.  On October 28, 2015, we issued 150,000 shares of common stock to an unaffiliated shareholder for a purchase price of $150,000, plus a warrant to purchase 150,000 shares of common stock for $1.50 per share.  Item 3.  Defaults Upon Senior Securities  None  Item 4.  Mine Safety Disclosures  Not Applicable.  Item 5.  Other Information  None  Item 6.  Exhibits  Exhibit No.DocumentLocation31Rule 13a-41(a)/15d-14(a) CertificationsIncluded32Section 1350 CertificationsIncluded101.INS(1)XBRL Instance DocumentIncluded101.SCH(1)XBRL Taxonomy Schema DocumentIncluded101.CAL(1)XBRL Taxonomy Calculation LinkbaseIncluded101.DEF(1)XBRL Taxonomy Definition Linkbase DocumentIncluded101.LAB(1)XBRL Taxonomy Label Linkbase DocumentIncluded101.PRE(1)XBRL Taxonomy Label Presentation Linkbase DocumentIncluded (2) XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under the sections.     SIGNATURES  In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.  ARTVENTIVE MEDICAL GROUP, INC.  November, 2015   /s/H James Graham  H. James Graham Chief Executive Officer Chief Financial Officer   /s/ Leon Rudakov Dr. Leon Rudakov President